Clinical trials: Sarcoma, Kaposi
Kaposi Sarcoma, HIV
Investigating Chemotherapy Treatments, Response and Subsets of HIV-associated Kaposi Sarcoma in Malawi
The purpose of this study is to identify important associations between complete and comprehensive clinical, laboratory, and genomic data derived from patients and tumor specimens, with prospectively recorded clinical outcomes.
- Trial name
- NCT03160183
- Where
- 2 sites in Malawi
- Volunteers
- 157 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
KSHV Inflammatory Cytokine Syndrome (KICS), KSHV
Natural History Study of the KSHV Inflammatory Cytokine Syndrome (KICS)
Background: KSHV inflammatory cytokine syndrome (KICS) is a newly recognized disease caused by Kaposi sarcoma-associated herpesvirus (KSHV). This virus can cause cancer. People with KICS can have severe symptoms.
- Conditions
- KSHV Inflammatory Cytokine Syndrome (KICS), KSHV, HHV-8
- Trial name
- NCT01419561
- Testing
- Zidovudine, Liposomal Doxorubicin, Valganiclovir
- Where
- United States
- Volunteers
- 140 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma, Kaposi, HIV Infections
A Study of Doxorubicin in the Treatment of AIDS-Related Kaposi's Sarcoma
To study the natural course of AIDS related Kaposi's sarcoma and to determine the usefulness and safety of weekly administration of small doses of doxorubicin.
- Trial name
- NCT00000996
- Testing
- Doxorubicin hydrochloride
- Where
- 12 sites in United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Sarcoma, Kaposi, HIV Infections
A Study of AZT Plus Human Interferon Alpha in the Treatment of AIDS-Related Kaposi's Sarcoma
To evaluate the safety and toxicity of combination therapy for AIDS-associated Kaposi's sarcoma with zidovudine (AZT) and two kinds of interferon alpha.
- Trial name
- NCT00001113
- Testing
- Interferon alfa-2a, Zidovudine, Interferon alfa-n1
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Sarcoma, Kaposi, HIV Infections
Phase II Study of Intravenous Novantrone(R) in the Treatment of AIDS Related Kaposi's Sarcoma
To study the toxicity and efficacy of IV mitoxantrone hydrochloride (Novantrone) in AIDS-related Kaposi's sarcoma.
- Trial name
- NCT00002259
- Testing
- Mitoxantrone hydrochloride
- Where
- United States
- Sponsor
- Lederle Laboratories
Sarcoma, Kaposi, HIV Infections
A Comparison of DOX-SL Versus Adriamycin Plus Bleomycin Plus Vincristine in the Treatment of Severe AIDS-Related Kaposi's Sarcoma
To determine the efficacy of Stealth liposomal doxorubicin hydrochloride (DOX-SL) in the treatment of severe AIDS-related Kaposi's sarcoma (KS) by comparison with the established therapy ABV: Adriamycin…
- Trial name
- NCT00002318
- Testing
- Doxorubicin hydrochloride (liposomal), Bleomycin sulfate, Vincristine sulfate
- Where
- 28 sites in United States
- Volunteers
- 225 people
- Sponsor
- Sequus Pharmaceuticals
Kaposi Sarcoma
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
Background: Kaposi Sarcoma (KS) is common in people with human immunodeficiency virus (HIV) but can also occur in people who do not have HIV.
- Trial name
- NCT04941274
- Testing
- Abemaciclib
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- National Cancer Institute (NCI)
Kaposi Sarcoma
PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma
Background: Kaposi sarcoma (KS) tumors grow on the skin, lymph nodes, lungs, bone, and gastrointestinal tract. KS often affects people with immune deficiencies, such as among people living with HIV or those with prior history of…
- Trial name
- NCT04303117
- Testing
- PDS01ADC, M7824
- Where
- United States
- Volunteers
- 80 people
- Sponsor
- National Cancer Institute (NCI)
Sarcoma, Kaposi, HIV Infections
The Safety and Effectiveness of Interferon Alfa-2B Plus Didanosine in Patients With Kaposi's Sarcoma
Primary: To evaluate the safety, toxicity, and antitumor activity of two doses of interferon alfa-2b (IFN-alpha) combined with a fixed dose of didanosine (ddI) in patients with Kaposi's sarcoma associated with HIV infection.
- Trial name
- NCT00001114
- Testing
- Interferon alfa-2b, Didanosine
- Where
- 13 sites in United States, Puerto Rico
- Volunteers
- 90 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Kaposi Sarcoma, HIV Infection
Development of Serologic Assays for Human Herpes Virus-8
Dr. Burbelo and colleagues have developed a technique for rapidly and quantitatively detecting antibody responses in sera to a variety of pathogens using recombinant proteins.
- Trial name
- NCT00395278
- Where
- United States
- Volunteers
- 394 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
HIV-infection/Aids, Human Herpesvirus 4 Infections
Inflammation and Co-Infections in D²EFT
i2-D²EFT substudy is an observational cohort nested within the parent D²EFT study (NCT03017872). D²EFT goal is to compare the standard of care second-line antiretroviral therapy in people living with HIV whose first-line non…
- Conditions
- HIV-infection/Aids, Human Herpesvirus 4 Infections, Cytomegalovirus Infections, Human Herpesvirus 8 Infection
- Trial name
- i2-D²EFT (NCT04183738)
- Testing
- NRTIs, Darunavir, Ritonavir
- Sponsor
- Kirby Institute
Sarcoma, Kaposi, HIV Infections
Comparison of Liposomal Doxorubicin Used Alone or in Combination With Bleomycin Plus Vincristine in the Treatment of Kaposi's Sarcoma in Patients With AIDS
To evaluate the safety and efficacy of liposomal doxorubicin hydrochloride ( DOX-SL ) alone or in combination with bleomycin and vincristine in the long-term treatment of AIDS-related Kaposi's sarcoma.
- Trial name
- NCT00001059
- Testing
- Doxorubicin hydrochloride (liposomal), Filgrastim, Bleomycin sulfate
- Where
- 17 sites in United States
- Volunteers
- 120 people
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Sarcoma, Kaposi, HIV Infections
A Randomized Phase III Clinical Trial of Daunoxome Versus Combination Chemotherapy With Adriamycin/Bleomycin/Vincristine (ABV) in the Treatment of HIV-Associated Kaposi's Sarcoma.
To compare the toxicity profiles (severity and time to onset from initiation of therapy) between daunorubicin (liposomal) and combination chemotherapy with doxorubicin/bleomycin/vincristine (ABV), with both regimens administered…
- Trial name
- NCT00002093
- Testing
- Daunorubicin (liposomal), Bleomycin sulfate, Vincristine sulfate
- Where
- 13 sites in United States
- Sponsor
- Nexstar Pharmaceuticals
Kaposi Sarcoma, HIV
Kaposi Sarcoma Chemotherapy and Research (KS-CARE)
This prospective, nonrandomized, open-label, single-arm, cohort study examines the effects of chemotherapy provided under local standard of care in patients with pathologically confirmed HIV-associated Kaposi Sarcoma (HIV-KS).
- Trial name
- KS-CARE (NCT06480773)
- Testing
- standard of care chemotherapy
- Where
- 2 sites in Malawi, South Africa
- Volunteers
- 127 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Kaposi Sarcoma (KS), HIV
Strategies to Improve Kaposi Sarcoma (KS) Outcomes in Zimbabwe
Kaposi sarcoma (KS) is an AIDS-related cancer and is the most commonly reported cancer in Zimbabwe. If it is found early on, it may be treatable with antiretroviral therapy (ARVs) alone and this will improve general well-being…
- Trial name
- SIKO (NCT01764360)
- Testing
- KS structured clinical care training
- Where
- Zimbabwe
- Volunteers
- 1,024 people
- Sponsor
- University of Colorado, Denver
Sarcoma, Kaposi, HIV Infections
A Phase I Trial of Tecogalan Sodium (DS-4152) Administered as an Infusion Every 21 Days
To evaluate the safety of different doses and dosing regimens of tecogalan sodium (DS-4152) and to establish the MTD at each of the different dosing schedules.
- Trial name
- NCT00002136
- Testing
- Tecogalan sodium
- Where
- United States
- Sponsor
- Daiichi Pharmaceuticals
Cervical Cancer, Kaposi Sarcoma
AYAHIV Role-based Responsibilities for Oncology-focused Workforce (ARROW)
Adolescents and young adults living with HIV experience higher premature mortality from cancer than their uninfected peers. In Zambia, because of multilevel barriers, interventions for early diagnosis and optimized treatment to…
- Conditions
- Cervical Cancer, Kaposi Sarcoma, Non Hodgkin Lymphoma
- Trial name
- NCT06004011
- Testing
- ARROW strategies, One-time education
- Where
- Zambia
- Volunteers
- 4,100 people
- Sponsor
- Implenomics
Large Cell Lymphoma Arising in KSHV-associated Multicentric Castleman Disease, Primary Effusion Lymphoma
Study of Pomalidomide Combined With Modified DA-EPOCH and Rituximab in KSHV-Associated Lymphomas
Background: The chemotherapy combination DA-EPOCH-RP includes the drugs etoposide (E), prednisone (P), vincristine (O), cyclophosphamide (C), doxorubicin (H), rituximab (R), and pomalidomide (P).
- Trial name
- NCT02228512
- Testing
- Pomalidomide, Rituximab, Prednisone
- Sponsor
- National Cancer Institute (NCI)
Kaposi's Sarcoma, HHV-8
BAY 43-9006 (Sorafenib) to Treat Patients With Kaposi's Sarcoma
Background: Kaposi's sarcoma (KS) is a disease in which cancer cells are found in the tissues under the skin or mucous membranes that line the mouth, nose, and anus.
- Conditions
- Kaposi's Sarcoma, HHV-8, KSHV
- Trial name
- NCT00287495
- Testing
- BAY 43-9006
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- National Cancer Institute (NCI)
Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma
Vismodegib and Gamma-Secretase/Notch Signalling Pathway Inhibitor RO4929097 in Treating Patients With Advanced or Metastatic Sarcoma
This randomized phase I/II clinical trial is studying the side effects and best dose of gamma-secretase/notch signalling pathway inhibitor RO4929097 when given together with vismodegib and to see how well they work in treating…
- Conditions
- Adult Alveolar Soft Part Sarcoma, Adult Angiosarcoma, Adult Desmoplastic Small Round Cell Tumor, Adult Epithelioid Hemangioendothelioma
- Trial name
- NCT01154452
- Testing
- Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- National Cancer Institute (NCI)